VOL 9 – NÚM 3 – DICIEMBRE 2024. NUEVOS MARCOS EN LA EVALUACIÓN DE TECNOLOGIAS SANITARIAS Y SUS EFECTOS EN MMHH
Cost-Per-Responder Analysis of Bimekizumab (IL-17A/F inhibitor) against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, based on Matching-Adjusted Indirect Comparisons (MAIC)
Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)
Recommendations for effective patient involvement in the assessment of medical devices
VOL 9 – NÚM 2 – SEPTIEMBRE 2024. ORGANIZACIÓN INSTITUCIONAL EN LA ATENCIÓN A LAS EERR
VOL 9 – NÚM 1 – ABRIL 2024. INNOVACIÓN TERAPÉUTICA EN EERR
Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimabnin Spain
VOL 8 – NÚM 3 – DICIEMBRE 2023. POLÍTICAS NACIONALES E INTERNACIONALES
